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the CC BY-NC-ND license (http://creaAbstract Recent studies demonstrated that bladder cancers can be grouped into basal and
luminal molecular subtypes that possess distinct biological and clinical characteristics. Basal
bladder cancers express biomarkers characteristic of cancer stem cells and epithelial-to-
mesenchymal transition (EMT). Patients with basal cancers tend have more advanced stage
and metastatic disease at presentation. In preclinical models basal human orthotopic xeno-
grafts are also more metastatic than luminal xenografts are, and they metastasize via an
EMT-dependent mechanism. However, preclinical and clinical data suggest that basal cancers
are also more sensitive to neoadjuvant chemotherapy (NAC), such that most patients with
basal cancers who are aggressively managed with NAC have excellent outcomes. Importantly,
luminal bladder cancers can also progress to become invasive and metastatic, but they appear
to do so via mechanisms that are much less dependent on EMT and may involve help from stro-
mal cells, particularly cancer-associated fibroblasts (CAFs). Although patients with luminal
cancers do not appear to derive much clinical benefit from NAC, the luminal tumors that
are infiltrated with stromal cells appear to be sensitive to anti-PDL1 antibodies and possibly
other immune checkpoint inhibitors. Therefore, neoadjuvant and/or adjuvant immunotherapy
may be the most effective approach in treating patients with advanced or metastatic infil-
trated luminal bladder cancers.
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Urothelial bladder cancer is a highly heterogeneous disease
with variable patterns of progression and responses to con-
ventional and targeted agents [1]. Histopathologically,
bladder cancers are grouped into twomajor subsets (papillary
and non-papillary) that pose distinct challenges for clinical
management [2]. Papillary bladder cancers rarely progress to
become muscle-invasive and metastatic, but they are highly
proneto recurrence,necessitating expensive life-longclinical
surveillancewith repeated surgical intervention [1,2]. Thus, a
top research priority is to identify agents that produce long-
term durable remissions in patients with this form of the
disease. There is also a need to identify biomarkers that
distinguish papillary cancers that pose no risk of progression
to muscle invasion from the smaller fraction that do, so that
more aggressive interventions can be applied early when the
chance of cure is greatest.
On the other hand, non-papillary bladder cancers have a
high risk of progression to muscle invasive and metastatic
disease [1], and they therefore pose a major threat to the
patient. It is believed that many of these cancers evolve
from carcinoma in situ (CIS) [2], although many patients
have advanced or metastatic disease at presentation. High
risk papillary and non-papillary non-muscle invasive cancers
are currently treated uniformly with intravesical bacillus
Calmette-Guerin (BCG) [1], which is a tuberculosis-like
mycobacterium that produces a local immune response
that mediates tumor regression [3]. However, even though
most (>70%) patients are initially rendered free of clinically
detectable disease, most will also develop recurrences that
can become BCG-unresponsive [4]. These tumors have a
high risk of progression, and at this point clinicians are
faced with the decision of whether to remove the bladder
(cystectomy) or to make another attempt at bladder pres-
ervation with a different intravesical or systemic regimen.
There are currently few viable candidates for the latter,
but new immunotherapy approaches hold promise. For
example, adenoviral interferon-alpha (Ad-IFNa) gene ther-
apy produced durable clinical responses in over a third of
patients with BCG-unresponsive disease in completed clin-
ical trials [5], and a phase III registration trial is now open
that could lead to FDA approval. There are also open clin-
ical trials examining the potential efficacy of immune
checkpoint blockade in these patients [6].
Muscle-invasive bladder cancers are also clinically het-
erogeneous [1]. Approximately half of patients are cured by
cystectomy with or without perioperative cisplatin-based
combination chemotherapy, but the others experience
very rapid disease progression to cisplatin-refractory and
metastatic disease [1]. Bladder cancers tend to metastasize
to the liver, lung, brain, and bone, but the molecular
mechanisms underlying organ-specific metastasis have not
been identified. Until very recently there were no effective
treatment options for patients with advanced and/or
metastatic disease, but exciting recent studies established
that immunotherapy with blocking anti-PD1 or -PDL1 anti-
bodies produces significant and durable benefit in about a
quarter of these patients [7,8], which prompted the FDA to
approve the anti-PDL1 antibody atezolizumab for advanced
bladder cancer in May 2016.Papillary and non-papillary bladder cancers appear to be
caused by distinct genomic alterations [2]. Papillary can-
cers are characterized by very high frequencies (>70%) of
activating mutations in the type 3 receptor for fibroblast
growth factor receptor (FGFR3) [9]. The mutations cause
constitutive ligand-independent dimerization of FGFR3,
leading to downstream MAP kinase activation that drives
proliferation. So far no mouse models of FGFR3-driven
papillary bladder tumorigenesis have been developed, but
expression of constitutively active mutant Ha-ras under the
control of a urothelium-specific (uroplakin) promoter cau-
ses papillary tumorigenesis [10], suggesting that FGFR3-
induced Ras pathway activation probably plays a central
role in transformation.
Non-papillary bladder cancers are more closely associ-
ated with inactivation of classical tumor suppressors, most
notably TP53 and RB1 [2,9]. It appears that TP53 mutations
are present in precursor lesions (CIS) [2,9], but most of the
published studies that support this conclusion used indirect
methods to identify p53-mutant tumors (i.e., immunohis-
tochemistry to detection high levels of p53 protein), so
more direct methods, such as next generation DNA
sequencing, will be required to confirm these results. Pre-
clinical studies confirmed that TP53 inactivation promotes
the emergence of CIS and muscle-invasive tumors in mice
exposed to the cigarette smoke nitrosamine carcinogen,
BBN [11] and combined inactivation of TP53 and RB1 via
expression of the SV40 large T antigen in the urothelium
also drives CIS and non-papillary tumorigenesis in mice [12].
Inactivation of TP53 and PTEN in the mouse urothelium
produced similar effects [13].
Recent lineage tracing studies suggest that papillary and
non-papillary bladder cancers also arise from different cells
of origin [14,15]. The papillary non-muscle invasive tumors
that arise spontaneously in BBN-treated mice originate via
transformation of a cell within the intermediate and/or
superficial (luminal) layer [14], whereas CIS and muscle-
invasive tumors arise from SONIC Hedgehog-expressing
basal cell(s) [15]. It will be interesting to determine
whether the genomic abnormalities that are observed in
papillary and non-papillary cancers are only permissive for
transformation in these more luminal or basal cells,
respectively.2. Intrinsic subtypes of bladder cancer
The introduction of whole genome technologies to catalog
all of the mRNA expression patterns and DNA alterations in
a given tumor has transformed our understanding of human
cancers. The Cancer Genome Atlas (TCGA) and the Inter-
national Cancer Genomics Consortium (ICGC) are examples
of two high profile collaborative public projects that have
exploited these capabilities to obtain comprehensive
genomic portraits of dozens of human cancers, and parallel
private efforts have further enhanced these efforts. One
approach that has been used very successfully has been to
use transcriptome profiling data to identify “molecular
subtypes” of cancers that share gene expression signatures
and by inference, biological properties. The highest profile
early example of the successful utilization of this approach
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human breast cancer. Their results revealed that breast
cancers can be grouped into at least 5 distinct subtypes
(luminal A, luminal B, HER2-enriched, basal-like, and
claudin-low) that behave clinically as distinct disease en-
tities [17]. Luminal tumors are associated with good long-
term outcomes, and patients with them obtain major
benefit from adjuvant therapy with selective estrogen re-
ceptor modulators (SERMs) but not from perioperative
chemotherapy [18e20]. On the other hand, basal-like,
HER2-enriched, or claudin-low tumors tend to be highly
aggressive, progressing rapidly to produce local and distant
metastases and shorter disease-specific survival. Patients
with these cancers do not benefit from adjuvant therapy
with SERMs, but many do obtain major benefit from peri-
operative chemotherapy, and patients with HER2-enriched
tumors also benefit from ERBB2 antagonists (i.e., Hercep-
tin) [18e20].
The gene expression signatures associated with the
breast cancer subtypes provide important information
about their likely biological properties. Luminal cancers
express genes characteristic of estrogen receptor activa-
tion and terminal differentiation within the normal mam-
mary epithelium [16]. Luminal B cancers are largely
distinguished from luminal A by higher expression of pro-
liferation biomarkers (i.e., Ki-67) [19], and they also
contain more TP53 mutations [21,22]. In contrast, basal-
like cancers express higher levels of biomarkers thatFigure 1 Reversible EMT mediates metastasis of basal bladder c
levels of “epithelial” biomarkers than did circulating tumor ce
expressed particularly high levels of the EMT transcription facto
returned to baseline in established metastases. Very similar observa
of squamous cell carcinoma. Based on Roth et al., Oncotarget 201
mesenchymal transition.characterize the basal layer of the normal mammary
epithelium and of other epithelial tissues, including TP63,
CD44, and high molecular weight cytokeratins (KRT5,6, and
14) [16,21,23]. These biomarkers are also enriched in
normal epithelial stem cells and cancer-associated stem
cells derived from epithelial lineage tumors. Basal-like tu-
mors are also enriched with biomarkers associated with
epithelial-to-mesenchymal transition (EMT) [19,21], a
developmental program that mediates wound healing and
can be reactivated to promote metastasis in solid tumors.
The claudin-low tumors are a subset of the basal-like can-
cers that express even higher levels of EMT and stem cell
biomarkers with lower expression of canonical epithelial
biomarkers, including E-cadherin, the claudins, and the
cytokeratins [19,24]. They express somewhat lower levels
of Ki-67 than do the basal-like tumors, and consequently
they are somewhat less sensitive to neoadjuvant chemo-
therapy (NAC) [19]. Preclinical studies concluded that
basal-like cancers can readily and spontaneously “switch”
between more epithelial and more mesenchymal states
[25], which may be important for their aggressive behaviors
(Fig. 1).
The application of similar methods to whole genome
mRNA expression profiling data from multiple independent
cohorts of bladder cancers revealed that they can also be
grouped into basal and luminal subtypes (Table 1) [26e29].
Most of this work was focused on muscle-invasive bladder
cancers, but the first deep characterization of non-muscleancers. Cells from orthotopic UM-UC3 tumors expressed higher
lls (CTCs) harvested from tumor-bearing animals. The CTCs
r, SNAIL (SNAI1). Interestingly, expression of EMT biomarkers
tions were made previously by Tsai et al. [49] in a mouse model
6 [59]. CAFs, cancer-associated fibroblasts; EMT, epithelial-to-
Table 1 Molecular subtypes of bladder cancer.
TCGA Lund MDACC UNC Properties
Cluster I UroA, GU Luminal Luminal FGFR3 mutations, papillary features
Cluster II Infiltrated P53-like Luminal CAFs, immune cells
Cluster III SCC-like, UroB Basal Basal-like Stem cell biomarkers, squamous features
Cluster IV Infiltrated P53-like Claudin-low EMT, CAFs, immune cells
Transcriptome profiling and unsupervised analyses were used by several groups to identify candidate molecular subtypes of bladder
cancer. Cross comparisons of the results obtained by 4 of the groups are presented above as examples. These comparisons are meant to
be illustrative rather than definitive, but they show how the overall concordance among the approaches was very high. Also see Aine
et al., Sci Rep 2015 [37] for a more detailed analysis.
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[30]. At the highest level, unsupervised hierarchical ana-
lyses revealed that non-muscle and muscle-invasive cancers
are highly distinct [31e33], driven largely by differential
expression of genes related to cell cycle progression, in-
vasion, migration, metastasis, and the DNA damage
response [34]. Muscle-invasive cancers also contain more
TP53 mutations and copy number variations characteristic
of chromosomal instability [34]. The work that has been
performed to date suggests that non-muscle invasive can-
cers can be further subdivided into 2e3 molecular subtypes
[30,35], and at least one of them appears to be enriched
with basal biomarkers [30], but additional work is required
to more precisely define the relationships between the
molecular subtypes of non-muscle invasive and muscle-
invasive cancers.
While the molecular portraits of non-muscle invasive
cancers are still emerging, much more is known about the
molecular subtypes of muscle-invasive bladder cancers.
Pioneering studies performed by Ho¨glund and colleagues at
the University of Lund identified 5 distinct subtypes of
muscle-invasive cancers that exhibited biologically infor-
mative gene expression signatures (Table 1) [35]. One of
the subtypes (SCC-like) was enriched with squamous his-
topathological features and biomarkers that characterize
squamous tumors in other organ sites, and patients with
these tumors exhibited relatively poor clinical outcomes. In
two of the subtypes (urobasal A and urobasal B) the hier-
archical patterns of differentiation-associated urothelial
biomarker expression were preserved. These tumors
expressed FGFR3-associated gene expression signatures
[35], suggesting that these tumors might be dependent on
FGFR3 signaling for their growth. Another subtype, termed
genomically unstable, was characterized by homogeneous
expression of E-cadherin and dysregulated expression of
biomarkers associated with cell cycle and the DNA damage
response.
Subsequently, TCGA [26] and several other groups
[27,28,36] independently identified molecular subtypes of
bladder cancer. Although each group defended the exis-
tence of different numbers of subtypes (n Z 2e4), the
overall concordance among them (and with the 5 subtypes
identified previously by the group at Lund) was extremely
high [37]. At the highest level, muscle-invasive bladder
cancers can be subdivided into basal and luminal subtypes
(Table 1). Basal bladder cancers can be further subdivided
into basal and claudin-low, and luminal bladder cancers can
be subdivided based on differential expression of bio-
markers associated with stromal cell infiltration andproliferation (Table 1). The Lund group’s uroA and genom-
ically unstable (GU) tumors correspond to luminal tumors
identified by the other groups that possess different pat-
terns of driver mutations (W. Choi, manuscript in prepara-
tion). UroA tumors are enriched with mutations in FGFR3
and other mutations that are also enriched in low-grade
papillary tumors, whereas the GU tumors contain more
inactivating TP53 and RB1 alterations and copy number
variations (W. Choi, manuscript in preparation). Interest-
ingly, the Lund group’s uroB subtype is also enriched with
activating FGFR3 mutations but is assigned to the basal
subtypes using the other classifiers, is enriched with squa-
mous features, and is associated with poor clinical out-
comes [35]. The uroB tumors may therefore correspond to a
“progressed” subset of the uroA cancers that have acquired
more aggressive properties.3. Implications of the basal and luminal
subtypes for metastasis
The clinical properties associated with the basal and
luminal subtypes of muscle-invasive bladder cancer provide
additional clues about their origins. Luminal bladder can-
cers are enriched with papillary histopathological features
[26], consistent with the idea that they correspond to low-
grade papillary tumors that acquired additional genomic
abnormalities and progressed to become muscle-invasive.
Conversely, basal tumors are often enriched with squa-
mous histopathological features [27,33,35], consistent with
clinical experience indicating that tumors with squamous
features tend to be more aggressive. It seems likely that
other bladder cancer histopathological variants will also
display luminal or basal biases. For example, we recently
showed that micropapillary bladder cancers correspond to
a clinically aggressive luminal variant characterized by
downregulation of miR-296 [38].
Like their breast cancer counterparts, basal and luminal
UCs are associated with different levels of benefit from
NAC. Initial studies demonstrated that rates of pathological
down staging were lower in “infiltrated” (p53-like) basal
and luminal tumors [27], although more recent results raise
questions about the relative impact of down staging on
survival in patients with basal or luminal cancers. We
recently performed subtype assignments on tumors
collected from patients enrolled in a phase II neoadjuvant
clinical trial of dose-dense MVAC plus bevacizumab (Avas-
tin). Rates of down staging in patients with basal or luminal
tumors were equivalent, but the patients with basal tumors
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patients with basal tumors benefited much more from NAC
than would have been expected based on down staging.
There are many possible explanations for this uncoupling of
pathological down staging of the primary tumor and sur-
vival, including differential effects of surgery, different
levels of subclinical metastases, and differential sensitivity
of those micro-metastases to NAC. All of these possibilities
are currently under investigation.
As compared with luminal tumors, basal UCs are asso-
ciated with advanced stage and metastatic disease at
clinical presentation [27]. Like their breast cancer coun-
terparts, basal UCs are characterized by high levels of stem
cell and EMT biomarkers [26e28], which are overexpressed
even further in the claudin-low subset of basal UCs [28].
Thus, the lethality associated with basal UCs in patients
who do not receive NAC appears to be linked more tightly to
their intrinsic invasive and metastatic potential as opposed
to intrinsic drug resistance.
3.1. EMT and UC metastasis
A very large body of preclinical and clinical evidence has
linked EMT to invasion, migration, stemness, and metas-
tasis [40e43]. During EMT polarized epithelial cells down-
regulate the homotypic adhesion molecule E-cadherin via
upregulation of families of transcription factors, including
ZEB1/2, SNAIL, SLUG, and TWIST, that block E-cadherin
expression [40]. Under normal conditions the epithelial
phenotype is maintained by expression of members of the
miR-200 family of microRNAs [44e46], which interact
directly with the transcripts encoding ZEB1 and ZEB2,
blocking their translation and promoting their degradation.
Conversely, ZEB1 and ZEB2 can bind to the promoters that
control expression of the miR-200 family and inhibit their
expression. Interestingly, TP63, which has been implicated
in epithelial “stemness” [47], can also block EMT by
inducing expression of miR-205 [48], which functions like
the members of the miR-200 family to inhibit ZEB1 and
ZEB2. In normal epithelial cells reversible EMT is initiated
by cytokines (particularly TGFb) that induce expression of
the EMT-associated transcription factors [40]. However, in
many cancers EMT appears to be driven by endogenous
mechanisms.
Reversible EMT plays a central role in wound healing by
enabling normal epithelial cells to temporarily adopt a
more invasive and migratory phenotype that promotes
wound closure [40]. These effects are coopted by cancer
cells to enable them to become invasive and metastatic
[40]. Using whole genome mRNA expression profiling,
Weinberg’s group [43] demonstrated that metastatic mu-
rine breast cancer cells overexpressed TWIST, and TWIST
knockdown blocked metastasis. Indeed, enforced over-
expression of TWIST was sufficient to promote “stemness”
in human breast cancer cells [42].
As is true in wound healing, it appears that EMT revers-
ibility also promotes metastasis. Using a conditional TWIST
mouse model, Yang’s group demonstrated that sustained,
enforced TWIST expression promoted tumor cell invasion
and migration in carcinogen-induced squamous cell carci-
nomas and resulted in the emergence of large numbers ofcirculating tumor cells (CTCs) in the peripheral blood, but it
did not lead to efficient formation of large metastases [49].
Rather, transient upregulation of TWIST resulted in a tran-
sient EMT and downstream CTC production that was asso-
ciated with the formation of large macro-metastases [49].
These effects were attributable to the differential effects
of EMT on invasion/migration on the one hand and on pro-
liferation on the other e the increase in the former was
associated with a significant decrease in the latter [49]. It is
interesting and potentially significant that there are similar
differences in baseline proliferation rates (as measured by
Ki-67 immunohistochemistry) in claudin-low and basal-like
breast cancers [19].
Weinberg’s group [25] also demonstrated that basal
breast cancer cell lines have a much higher tendency to
undergo spontaneous EMT than luminal breast cancer cell
lines do. They linked these effects to a “poised” chromatin
conformation within the ZEB1 promoter, enabling it to
respond rapidly to environmental cues [25]. The molecular
mechanisms that mediate this chromatin phenotype have
not been defined, although as discussed above, a role for
TP63 is very attractive given its established roles in main-
taining both “stemness” and an “epithelial” phenotype.
Modulation of TP63 expression could represent an impor-
tant mechanism for effecting rapid and reversible changes
in EMT transcription factor expression. Another possible
mechanism could involve fluctuations in the expression of
members of the miR-200 family of microRNAs [45].
Although luminal breast cancers are associated with lower
rates of earlymetastasis, a significant fraction ofwomenwith
luminal cancers do develop late (mostly bone) metastases.
Therefore, luminal cancer cells are clearly capable of meta-
sizing, but they may require “help” from cells in the tumor
microenvironment [50e52], including cancer-associated fi-
broblasts (CAFs) [51]. Work from Massague’s group [51]
demonstrated that fibroblasts promoted bone metastasis in
human breast cancer xenografts via Src pathway activation
and production of specific chemokines and cytokines, most
notably CXCL12 and IGF-1. CAFs appeared to “prime” breast
cancer cells within the primary tumor for subsequent growth
in the bone microenvironment by upregulating these Src-
related pathways [51].
A significant fraction of primary luminal human breast
cancers is infiltrated with CAFs [25], and it is possible that
they enable them to metastasize without undergoing full
EMT. The existence of EMT-dependent and -independent
pathways of metastasis has recently been documented in
two high profile studies performed in genetically engi-
neered mouse models of breast and pancreatic cancer
[53,54].
3.2. EMT, CAFs and UC metastasis
Our group has a longstanding interest in defining the mo-
lecular mechanisms that mediate UC metastasis. Early
studies demonstrated that invasion and metastasis in pa-
tients were associated with upregulation of matrix
metalloproteinase-9 (MMP9) and downregulation of E-cad-
herin [55,56], changes that are consistent with EMT [57].
We also developed some of the first preclinical mouse
models to study UC metastasis using an approach termed
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involves implanting human cancer cells into the anatomi-
cally correct organ microenvironment (in this case, the
bladder wall), allowing the tumors to grow until the animals
become moribund, harvesting cells from any metastases
that develop, and reimplanting them back into the bladder.
This process is repeated until metastases are consistently
observed in almost all of the mice [58].
We initially used this approach to generate metastatic
variants of the 253J human bladder cancer cell line [58].
More recently we launched studies to systematically mea-
sure the tumorigenic and metastatic potentials of the 30
human cell lines in our panel, and we recently published
results obtained with the first 5 (UM-UC3, UM-UC6, UM-UC9,
UM-UC13, and UM-UC14) [59]. Of them, only the UM-UC3
and UM-UC13 lines reliably produced metastases after
orthotopic recycling in nude mice [59]. The UM-UC3 and
UM-UC13 lines were also the only cells in the panel that
expressed biomarkers characteristic of EMT [48].
Weused thecomplete TCGAdataset to developa 515-gene
prediction analysis of microarrays (PAM) classifier that
assigned primary human tumors to the basal or luminal sub-
type with a high degree of accuracy (A. Ochoa, manuscript
under revision). Using this classifier, we assigned all 30 lines in
our panel of human bladder cancer cells to the basal or
luminal subtype. The UM-UC3 and UM-UC13 cells were stably
assigned to the basal subtype, whereas the UM-UC6, UM-UC9,
and UM-UC14 lines were all stably assigned to the luminal
subtype. This result was not surprising given that EMT bio-
markers are generally enriched in basal cancers, but it sup-
ported the overall hypothesis that basal cancers are
intrinsically more metastatic than luminal cancers are.
As described above, a recent study concluded that
reversible EMT plasticity was required for optimal forma-
tion of macro-metastases in a mouse model of squamous
cell carcinoma. To investigate whether the same effects
were required for metastasis in our preclinical models, we
performed whole genome mRNA expression profiling on
matched primary tumors, CTCs, and established macro-
metastases from the UM-UC3 model [59]. Consistent with
the previous work, many EMT markers were upregulated in
the CTCs relative to the primary tumors or established
metastases, but the most striking change observed was
upregulation of SNAIL (SNAI1) in the CTCs [59]. Therefore,
in order to directly determine whether this upregulation of
SNAIL was required for metastasis, we transduced the
“recycled” UM-UC3 cells with a conditional, doxycycline-
regulated lentiviral shRNA construct specific for SNAIL and
examined the effects of transient knockdown on CTC pro-
duction and metastasis. Administration of doxycycline to
the drinking water blocked both in mice bearing established
UM-UC3 tumors, and removal of doxycycline restored CTC
production and subsequent metastasis [59]. Therefore,
SNAIL knockdown caused a reversible inhibition of both
events, consistent with the hypothesis.
Although basal bladder cancers (like their breast cancer
counterparts) appear to be intrinsically more metastatic,
luminal bladder cancers can progress to become muscle-
invasive and metastatic as well. It seems likely that CAFs
play an important role in promoting metastasis of luminal
cancers. Indirect support for this hypothesis came from our
recently completed neoadjuvant phase II trial of dose-dense MVAC plus the blocking anti-VEGF antibody, bev-
acizumab (Avastin) [39]. Post-treatment tumors from
resistant patients were enriched with CAFs and member-
ship in the MDACC “p53-like”/infiltrated subtype [39],
consistent with our original findings in an independent
cohort [27]. Importantly, many patients with these tumors
developed bone metastases, and p53-like tumors were
associated with the shortest disease-specific survival [39].
We have optimized methods for isolating CAFs from bladder
cancers and have confirmed that they express high levels of
the biomarkers that are associated with the p53-like sub-
type. We plan to combine them with recycled basal and
luminal human bladder cancer cells to determine whether
the CAFs promote chemoresistance and metastasis. If so,
the models will serve as powerful model systems to identify
the molecular mechanisms involved.
4. Summary and conclusion
Like their breast cancer counterparts, basal bladder cancers
are enriched with EMT and cancer stem cell biomarkers and
are intrinsically aggressive. In preclinicalmodels basal human
bladder cancer cell lines are more invasive and metastatic,
and they appear to metastasize via EMT-dependent mecha-
nisms. However, basal bladder cancers also appear to be
sensitive to NAC, and many patients with basal cancers
treated with NAC have excellent long-term outcomes.
Therefore, patients with basal cancers should be identified as
quickly as possible after diagnosis so that they can be
managed with frontline therapy aggressively to prevent
metastasis.
Although luminal cancers appear to be less prone to
metastasize, a significant fraction of them still do. NAC
appears to produce less benefit in patients with luminal
tumors in general and particularly in patients whose tumors
are infiltrated with CAFs. In patients treated with NAC,
those with p53-like infiltrated tumors appear to be at the
highest risk for developing metastases, particularly to the
bone, and they exhibit the shortest disease-specific sur-
vival. Therefore, novel approaches are urgently needed for
patients with these CAF-infiltrated tumors. The preliminary
observation that the anti-PDL1 antibody atezolizumab
produced the most clinical impact in patients with infil-
trated (TCGA cluster II) tumors suggests that perioperative
therapy with immune checkpoint blockade might be the
best option for these patients. This hypothesis will need to
be tested prospectively in future clinical trials.Conflicts of interest
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